| Disease |
Protocol |
Description |
| Anal Cancer |
RTOG 9811 |
RT + 5-FU + Mito-C vs. RT + 5-FU + CDDP |
| Bile Duct Cancer |
UAB 0001 |
Phase II Rebeccamycin |
| Colon/Rectal Cancer |
UAB 0144 |
Phase II study of oral Xeloda in combination with intravenous Irinotecan |
| Colon/Rectal Cancer |
UAB 0237 |
Phase II multicenter study of Erbitux™ (Cetuximab) in patients with metastatic colorectal carcinoma |
| Colon/Rectal Cancer |
UAB 0135 |
Phase II study safety and immunogenicity of ALVAC-CEA/B7.1 vaccine |
| Colon/Rectal Cancer |
UAB 0249 |
A feasibility study of Oxaliplatin in combination with an infusional or weekly bolus 5-FU/LV or Capecitabine as first line treatment of patients with advanced colorectal cancer |
| Colon/Rectal Cancer |
ECOG N9841 |
Randomized Phase II equivalence trial of Irinotecan vs. Oxaliplatin in combination with an infusional or weekly bolus 5-FU/LV or Capecitabine as first line treatment of patients with advanced colorectal cancer |
| Colon/Rectal Cancer |
UAB 0040 |
Phase IIB evaluation of Cyclooxygenase-2 activity in surgically resected primary colorectal adenomas and carcinomas after 7 days pretreatment with Celecoxib |
| Esophageal Cancer |
UAB 0032 |
A Phase II study of Irinotecan and Taxotere with concurrent radiotherapy as a preoperative treatment in resectable esophageal cancer |
| Gallbladder Cancer |
UAB 0001 |
Phase II Rebeccamycin |
| Liver Cancer |
UAB 0034 |
A Phase I/II open label study of T138057-sodium in patients with advanced, surgically unresectable hepatocellular carcinoma |
| Liver Cancer |
UAB 0001 |
Phase II Rebeccamycin |
| Pancreatic Cancer |
UAB 0105 |
Phase III PN-401 with High Dose 5FU vs. Gemcitabine |
| Pancreatic Cancer |
UAB 0133 |
Phase I/II open label study of Capecitabine with concurrent radiotherapy |
| Pancreatic Cancer |
UAB 0243 |
Randomized, placebo-controlled, double blind Phase II study of Gemcitabine + Ly293111 compared to Gemcitabine + placebo in patients with locally advanced or metastatic pancreatic cancer |
| All cancers may be elligible |
UAB 0142 |
Phase I DX-8951f in patients with liver dysfunction |
| All cancers may be elligible |
UAB 0143 |
Phase I DX-891f in patients with renal dysfunction |